Review





Similar Products

95
MedChemExpress ferric ammonium citrate fac
(A) Glioma cell survival at 24 h after SS treatment. (B) Glioma cell survival after pretreatment with <t>DFO,</t> <t>FAC,</t> Fer‐1, and Lip‐1, respectively, for 1 h before SS treatment. (C–F) Intracellular ROS, MDA, GSH/GSSG, and ferrous ion levels at 6, 12, and 24 h after SS treatment, with and without DFO, Fer‐1, Lip‐1, and FAC pretreatment for 1 h before SS treatment, respectively. (G) Glioma cell survival after SS treatment, with and without pretreatment with NAC and GSH for 1 h before SS treatment, respectively. (H) Western blots of ferroptosis‐related protein expression after SS treatment. Cell survival was assessed by the CCK‐8 assay. (I) Western blots of ATF3 expression in the cytoplasm and nuclei of SS‐treated cells. (J) Viability of cells treated with siATF3 followed by SS. (K–N) Ferrous ion, MDA, GSH/GSSG, and ROS levels in cells treated with siATF3 followed by SS. (O) Confocal microscopic images of ATF3 immunofluorescence in U251 cells treated with SS. (P, Q) Confocal microscopy images and fluorescence intensity measurements of mitochondrial superoxide in SS‐ and siATF3‐treated U251 and T98 cells. * p < 0.01 versus control, # p < 0.01 versus treatment group.
Ferric Ammonium Citrate Fac, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/iii/Ammonium+iron(III)+citrate/pmc13695081-47-4-32
Average 95 stars, based on 1 article reviews
ferric ammonium citrate fac - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

99
Vazyme Biotech Co hiscript iii rt supermix for qpcr
(A) Glioma cell survival at 24 h after SS treatment. (B) Glioma cell survival after pretreatment with <t>DFO,</t> <t>FAC,</t> Fer‐1, and Lip‐1, respectively, for 1 h before SS treatment. (C–F) Intracellular ROS, MDA, GSH/GSSG, and ferrous ion levels at 6, 12, and 24 h after SS treatment, with and without DFO, Fer‐1, Lip‐1, and FAC pretreatment for 1 h before SS treatment, respectively. (G) Glioma cell survival after SS treatment, with and without pretreatment with NAC and GSH for 1 h before SS treatment, respectively. (H) Western blots of ferroptosis‐related protein expression after SS treatment. Cell survival was assessed by the CCK‐8 assay. (I) Western blots of ATF3 expression in the cytoplasm and nuclei of SS‐treated cells. (J) Viability of cells treated with siATF3 followed by SS. (K–N) Ferrous ion, MDA, GSH/GSSG, and ROS levels in cells treated with siATF3 followed by SS. (O) Confocal microscopic images of ATF3 immunofluorescence in U251 cells treated with SS. (P, Q) Confocal microscopy images and fluorescence intensity measurements of mitochondrial superoxide in SS‐ and siATF3‐treated U251 and T98 cells. * p < 0.01 versus control, # p < 0.01 versus treatment group.
Hiscript Iii Rt Supermix For Qpcr, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/iii/HiScript+III+RT+SuperMix+for+qPCR+%2BgDNA+wiper/pm42908380-364-14-22
Average 99 stars, based on 1 article reviews
hiscript iii rt supermix for qpcr - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

96
Revvity ivis optical imaging platform
(A) Glioma cell survival at 24 h after SS treatment. (B) Glioma cell survival after pretreatment with <t>DFO,</t> <t>FAC,</t> Fer‐1, and Lip‐1, respectively, for 1 h before SS treatment. (C–F) Intracellular ROS, MDA, GSH/GSSG, and ferrous ion levels at 6, 12, and 24 h after SS treatment, with and without DFO, Fer‐1, Lip‐1, and FAC pretreatment for 1 h before SS treatment, respectively. (G) Glioma cell survival after SS treatment, with and without pretreatment with NAC and GSH for 1 h before SS treatment, respectively. (H) Western blots of ferroptosis‐related protein expression after SS treatment. Cell survival was assessed by the CCK‐8 assay. (I) Western blots of ATF3 expression in the cytoplasm and nuclei of SS‐treated cells. (J) Viability of cells treated with siATF3 followed by SS. (K–N) Ferrous ion, MDA, GSH/GSSG, and ROS levels in cells treated with siATF3 followed by SS. (O) Confocal microscopic images of ATF3 immunofluorescence in U251 cells treated with SS. (P, Q) Confocal microscopy images and fluorescence intensity measurements of mitochondrial superoxide in SS‐ and siATF3‐treated U251 and T98 cells. * p < 0.01 versus control, # p < 0.01 versus treatment group.
Ivis Optical Imaging Platform, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/iii/IVIS+optical+imaging+platform/custom%40cls158738%4042976903
Average 96 stars, based on 1 article reviews
ivis optical imaging platform - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

86
Instron Corp groups three point
(A) Glioma cell survival at 24 h after SS treatment. (B) Glioma cell survival after pretreatment with <t>DFO,</t> <t>FAC,</t> Fer‐1, and Lip‐1, respectively, for 1 h before SS treatment. (C–F) Intracellular ROS, MDA, GSH/GSSG, and ferrous ion levels at 6, 12, and 24 h after SS treatment, with and without DFO, Fer‐1, Lip‐1, and FAC pretreatment for 1 h before SS treatment, respectively. (G) Glioma cell survival after SS treatment, with and without pretreatment with NAC and GSH for 1 h before SS treatment, respectively. (H) Western blots of ferroptosis‐related protein expression after SS treatment. Cell survival was assessed by the CCK‐8 assay. (I) Western blots of ATF3 expression in the cytoplasm and nuclei of SS‐treated cells. (J) Viability of cells treated with siATF3 followed by SS. (K–N) Ferrous ion, MDA, GSH/GSSG, and ROS levels in cells treated with siATF3 followed by SS. (O) Confocal microscopic images of ATF3 immunofluorescence in U251 cells treated with SS. (P, Q) Confocal microscopy images and fluorescence intensity measurements of mitochondrial superoxide in SS‐ and siATF3‐treated U251 and T98 cells. * p < 0.01 versus control, # p < 0.01 versus treatment group.
Groups Three Point, supplied by Instron Corp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/iii/bending+point+tester+three/pmc13251218-426-13-18
Average 86 stars, based on 1 article reviews
groups three point - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

99
Vazyme Biotech Co hiscript iii qrt supermix
(A) Glioma cell survival at 24 h after SS treatment. (B) Glioma cell survival after pretreatment with <t>DFO,</t> <t>FAC,</t> Fer‐1, and Lip‐1, respectively, for 1 h before SS treatment. (C–F) Intracellular ROS, MDA, GSH/GSSG, and ferrous ion levels at 6, 12, and 24 h after SS treatment, with and without DFO, Fer‐1, Lip‐1, and FAC pretreatment for 1 h before SS treatment, respectively. (G) Glioma cell survival after SS treatment, with and without pretreatment with NAC and GSH for 1 h before SS treatment, respectively. (H) Western blots of ferroptosis‐related protein expression after SS treatment. Cell survival was assessed by the CCK‐8 assay. (I) Western blots of ATF3 expression in the cytoplasm and nuclei of SS‐treated cells. (J) Viability of cells treated with siATF3 followed by SS. (K–N) Ferrous ion, MDA, GSH/GSSG, and ROS levels in cells treated with siATF3 followed by SS. (O) Confocal microscopic images of ATF3 immunofluorescence in U251 cells treated with SS. (P, Q) Confocal microscopy images and fluorescence intensity measurements of mitochondrial superoxide in SS‐ and siATF3‐treated U251 and T98 cells. * p < 0.01 versus control, # p < 0.01 versus treatment group.
Hiscript Iii Qrt Supermix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/iii/HiScript+IV+All-in-One+Ultra+RT+SuperMix+for+qPCR/pm42914648-95-14-19
Average 99 stars, based on 1 article reviews
hiscript iii qrt supermix - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
Vazyme Biotech Co hiscript iii rt supermix
(A) Glioma cell survival at 24 h after SS treatment. (B) Glioma cell survival after pretreatment with <t>DFO,</t> <t>FAC,</t> Fer‐1, and Lip‐1, respectively, for 1 h before SS treatment. (C–F) Intracellular ROS, MDA, GSH/GSSG, and ferrous ion levels at 6, 12, and 24 h after SS treatment, with and without DFO, Fer‐1, Lip‐1, and FAC pretreatment for 1 h before SS treatment, respectively. (G) Glioma cell survival after SS treatment, with and without pretreatment with NAC and GSH for 1 h before SS treatment, respectively. (H) Western blots of ferroptosis‐related protein expression after SS treatment. Cell survival was assessed by the CCK‐8 assay. (I) Western blots of ATF3 expression in the cytoplasm and nuclei of SS‐treated cells. (J) Viability of cells treated with siATF3 followed by SS. (K–N) Ferrous ion, MDA, GSH/GSSG, and ROS levels in cells treated with siATF3 followed by SS. (O) Confocal microscopic images of ATF3 immunofluorescence in U251 cells treated with SS. (P, Q) Confocal microscopy images and fluorescence intensity measurements of mitochondrial superoxide in SS‐ and siATF3‐treated U251 and T98 cells. * p < 0.01 versus control, # p < 0.01 versus treatment group.
Hiscript Iii Rt Supermix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/iii/HiScript+III+RT+SuperMix+for+qPCR+%2BgDNA+wiper/pm42910938-259-24-29
Average 99 stars, based on 1 article reviews
hiscript iii rt supermix - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

99
Vazyme Biotech Co hiscript iii all
(A) Glioma cell survival at 24 h after SS treatment. (B) Glioma cell survival after pretreatment with <t>DFO,</t> <t>FAC,</t> Fer‐1, and Lip‐1, respectively, for 1 h before SS treatment. (C–F) Intracellular ROS, MDA, GSH/GSSG, and ferrous ion levels at 6, 12, and 24 h after SS treatment, with and without DFO, Fer‐1, Lip‐1, and FAC pretreatment for 1 h before SS treatment, respectively. (G) Glioma cell survival after SS treatment, with and without pretreatment with NAC and GSH for 1 h before SS treatment, respectively. (H) Western blots of ferroptosis‐related protein expression after SS treatment. Cell survival was assessed by the CCK‐8 assay. (I) Western blots of ATF3 expression in the cytoplasm and nuclei of SS‐treated cells. (J) Viability of cells treated with siATF3 followed by SS. (K–N) Ferrous ion, MDA, GSH/GSSG, and ROS levels in cells treated with siATF3 followed by SS. (O) Confocal microscopic images of ATF3 immunofluorescence in U251 cells treated with SS. (P, Q) Confocal microscopy images and fluorescence intensity measurements of mitochondrial superoxide in SS‐ and siATF3‐treated U251 and T98 cells. * p < 0.01 versus control, # p < 0.01 versus treatment group.
Hiscript Iii All, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/iii/HiScript+III+All-in-one+RT+SuperMix+Perfect+for+qPCR/pm42905834-304-4-12
Average 99 stars, based on 1 article reviews
hiscript iii all - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


(A) Glioma cell survival at 24 h after SS treatment. (B) Glioma cell survival after pretreatment with DFO, FAC, Fer‐1, and Lip‐1, respectively, for 1 h before SS treatment. (C–F) Intracellular ROS, MDA, GSH/GSSG, and ferrous ion levels at 6, 12, and 24 h after SS treatment, with and without DFO, Fer‐1, Lip‐1, and FAC pretreatment for 1 h before SS treatment, respectively. (G) Glioma cell survival after SS treatment, with and without pretreatment with NAC and GSH for 1 h before SS treatment, respectively. (H) Western blots of ferroptosis‐related protein expression after SS treatment. Cell survival was assessed by the CCK‐8 assay. (I) Western blots of ATF3 expression in the cytoplasm and nuclei of SS‐treated cells. (J) Viability of cells treated with siATF3 followed by SS. (K–N) Ferrous ion, MDA, GSH/GSSG, and ROS levels in cells treated with siATF3 followed by SS. (O) Confocal microscopic images of ATF3 immunofluorescence in U251 cells treated with SS. (P, Q) Confocal microscopy images and fluorescence intensity measurements of mitochondrial superoxide in SS‐ and siATF3‐treated U251 and T98 cells. * p < 0.01 versus control, # p < 0.01 versus treatment group.

Journal: CNS Neuroscience & Therapeutics

Article Title: ATF3 Promotes Solasonine‐Triggered Ferroptosis in Glioma Cells by Suppressing Glycolysis

doi: 10.1002/cns.71226

Figure Lengend Snippet: (A) Glioma cell survival at 24 h after SS treatment. (B) Glioma cell survival after pretreatment with DFO, FAC, Fer‐1, and Lip‐1, respectively, for 1 h before SS treatment. (C–F) Intracellular ROS, MDA, GSH/GSSG, and ferrous ion levels at 6, 12, and 24 h after SS treatment, with and without DFO, Fer‐1, Lip‐1, and FAC pretreatment for 1 h before SS treatment, respectively. (G) Glioma cell survival after SS treatment, with and without pretreatment with NAC and GSH for 1 h before SS treatment, respectively. (H) Western blots of ferroptosis‐related protein expression after SS treatment. Cell survival was assessed by the CCK‐8 assay. (I) Western blots of ATF3 expression in the cytoplasm and nuclei of SS‐treated cells. (J) Viability of cells treated with siATF3 followed by SS. (K–N) Ferrous ion, MDA, GSH/GSSG, and ROS levels in cells treated with siATF3 followed by SS. (O) Confocal microscopic images of ATF3 immunofluorescence in U251 cells treated with SS. (P, Q) Confocal microscopy images and fluorescence intensity measurements of mitochondrial superoxide in SS‐ and siATF3‐treated U251 and T98 cells. * p < 0.01 versus control, # p < 0.01 versus treatment group.

Article Snippet: Ferrostatin‐1 (Fer‐1), deferoxamine (DFO), ferric ammonium citrate (FAC), liproxstatin‐1 (Lip‐1), adenosine triphosphate (ATP), bafilomycin A1 (Baf‐A1), 3‐methyladenine (3MA), N‐acetylcysteine (NAC), reduced L‐glutathione (GSH), sodium 4‐phenylbutyrate (4‐PBA), and sodium 2‐oxopropanoate were purchased from MedChemExpress (NJ, USA).

Techniques: Western Blot, Expressing, CCK-8 Assay, Confocal, Immunofluorescence, Microscopy, Fluorescence, Control